T1	Participants 51 83	small cell lung cancer patients.
T2	Participants 195 233	small cell lung cancer (SCLC) patients
T3	Participants 330 504	11 patients received either standard (four weekly) chemotherapy with ifosfamide, carboplatin, and etoposide (ICE) or accelerated (two weekly) ICE with filgrastim (granulocyte
